Background Recurrent venous thromboembolism (VTE) is common. Current guidelines
suggest that patients with unprovoked VTE should continue anticoagulants unless they have …

Background—Predicting the risk of recurrent venous thromboembolism (VTE) in an
individual patient is often not feasible. We aimed to develop a simple risk assessment model …

To optimize patient outcomes with anticoagulation for venous thromboembolism (VTE), it is
essential to assess patients for their recurrence risk. In this article, I will review the impact of …

Abstract Background and Aims Patients with unprovoked venous thromboembolism (VTE)
have a high recurrence risk, and guidelines suggest extended-phase anticoagulation. Many …

Objective To optimize decision making for anticoagulant treatment duration after incident
venous thromboembolism, we derived and internally validated two clinically applicable sex …

Introduction Prediction models for recurrence and bleeding are infrequently used when
deciding on anticoagulant treatment duration after venous thromboembolism (VTE) due to …

Background Patients with unprovoked (ie, without the presence of apparent transient risk
factors such as recent surgery) venous thromboembolism (VTE) are at risk of recurrence if …

Background In order to stratify patients with a first unprovoked venous thromboembolism
(VTE) according to their recurrence risk and to identify those who would actually benefit from …

Venous thromboembolism (VTE) is a common and chronic disease with a considerable risk
of recurrence. Patients with unprovoked (in the absence of a transient risk factor) VTE have a …

Venous thromboembolism (VTE) is a disease, which often recurs. The recurrence risk is
highest in patients with unprovoked proximal deep-vein thrombosis (VT) or pulmonary …